文献速递神经创伤神经重症

促红细胞生成素治疗创伤性脑损伤疗效与安全性的Meta分析及试验序贯分析:新范式

Meta-Analysis with Trial Sequential Analysis on the Efficacy and Safety of Erythropoietin in Traumatic Brain Injury: A New Paradigm.
PubMed 文献 · World Neurosurg · 2020-05-22

该系统评价与Meta分析纳入7项随机对照试验,评估促红细胞生成素(EPO)在创伤性脑损伤中的疗效与安全性。合并结果显示EPO显著降低6个月死亡率(OR 0.65,95%CI 0.43-0.97,P=0.04),但院内死亡率、良好结局率及深静脉血栓发生率均无显著差异。试验序贯分析提示现有信息不足以得出确定性结论,需要大型试验进一步评估。

要点

  • EPO显著降低6个月死亡率(OR 0.65,95%CI 0.43-0.97,P=0.04)。
  • 院内死亡率、良好结局率及深静脉血栓发生率无显著差异。
  • 试验序贯分析提示累积信息不足,需大型试验进一步评估。

核心结论

  • EPO似乎有助于降低6个月死亡率,但对院内死亡率、神经功能结局及深静脉血栓风险的影响未达统计学显著。
  • 试验序贯分析提示需要大型试验以更系统的方式评估EPO在创伤性脑损伤患者中的作用。

研究设计与样本

  • 系统检索PubMed、Cochrane图书馆数据库和Google Scholar截至2019年12月的随机对照试验,最终纳入7项随机对照试验进行定量分析。
  • 采用试验序贯分析评估是否需要进一步研究。

主要发现

  • 合并估计显示EPO显著降低6个月死亡率(OR 0.65,95%CI 0.43-0.97,P=0.04)。
  • 院内死亡率无显著差异(OR 0.84,95%CI 0.31-2.32,P=0.74)。
  • 良好结局率无显著差异(OR 1.58,95%CI 0.84-2.99,P=0.16)。
  • 深静脉血栓发生率两组无显著差异(RD -0.02,95%CI -0.06至0.02,P=0.41)。
  • 试验序贯分析显示累积信息不足以做出任何确定性结论。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验序贯分析显示累积信息不足以做出任何确定性结论。
  • 试验序贯分析提示需要大型试验以更系统的方式评估EPO在创伤性脑损伤患者中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Erythropoietin (EPO) has been shown to be beneficial in traumatic brain injury (TBI). We have attempted to quantitatively synthesize the findings of current randomized controlled trials (RCTs) in this meta-analysis and analyzed the need for further trials using trial sequential analysis (TSA). METHODS: A systematic search was performed in PubMed, the Cochrane Library databases, and Google Scholar for RCTs until December 2019 evaluating the role of EPO in patients with TBI. Seven RCTs were finally included in the quantitative analysis. TSA was done to evaluate the need for further studies. RESULTS: The pooled estimate demonstrated that EPO significantly reduced mortality at 6 months (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.43-0.97; P = 0.04) but not in hospital mortality (OR, 0.84; 95% CI, 0.31-2.32; P = 0.74). There was no significant difference in the rate of favorable outcomes with EPO (OR, 1.58; 95% CI, 0.84-2.99; P = 0.16). The rate of deep vein thrombosis (RD, -0.02; 95% CI, -0.06 to 0.02; P =0.41) was also not found to be significantly different in the 2 groups. TSA showed that the accrued information is insufficient to make any definitive conclusions. CONCLUSIONS: EPO seems to be beneficial in terms of reducing 6-month mortality, however, its effect on in-hospital mortality, neurologic outcomes, and risk of deep vein thrombosis fails to reach statistical significance. TSA suggests a need for large trials to evaluate the role of EPO in patients with TBI in a more systematic way.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Katiyar V, Chaturvedi A, Sharma R, et al. Meta-Analysis with Trial Sequential Analysis on the Efficacy and Safety of Erythropoietin in Traumatic Brain Injury: A New Paradigm. World Neurosurg. 2020. PMID: 32450313. doi:10.1016/j.wneu.2020.05.142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。